Evaluation of desmopressin in critically ill patients with hyponatremia requiring 3% hypertonic saline

Link to article at PubMed

Am J Med Sci. 2021 Apr 1:S0002-9629(21)00103-8. doi: 10.1016/j.amjms.2021.03.012. Online ahead of print.


BACKGROUND: Desmopressin (DDAVP) is often used for hyponatremia management but has been associated with increases in hospital length of stay and duration of hypertonic saline use. The purpose of this study was to evaluate hyponatremia management strategies and their effect on sodium correction in critically ill patients requiring 3% hypertonic saline (3HS).

METHODS: This retrospective, single-center study included patients with hyponatremia (serum sodium ≤ 125 mEq/L) receiving 3HS from May 31 2015 to May 31 2019. Patients were divided into those who received 3HS for hyponatremia management (HTS) and those who received proactive or reactive DDAVP in addition to 3HS (D-HTS). Patients in either group could receive rescue DDAVP. The primary outcome was the percentage of patients achieving goal sodium correction of 5-10 mEq/L 24 hours after 3HS start.

RESULTS: Goal sodium correction was achieved in 52.5% of patients in HTS compared to 65.6% of patients in D-HTS (p = 0.21). Patients in HTS had a shorter duration of 3HS infusion (p = 0.0022) with no difference in ICU length of stay, free water intake, urine output, or serum sodium increases 12 and 24 hours after receiving 3HS. Overcorrection during any 24- or 48-hour period was not statistically different in both groups.

CONCLUSION: Patients in HTS and D-HTS had similar rates of achieving goal sodium correction at 24 hours. A proactive or reactive DDAVP strategy led to an increase in 3HS duration and total amount with no significant difference in rates of overcorrection. Prospective, randomized studies assessing standardized strategies for hyponatremia management and DDAVP administration are needed.

PMID:33812910 | DOI:10.1016/j.amjms.2021.03.012

Leave a Reply

Your email address will not be published.